ea0073aep100 | Calcium and Bone | ECE2021
Zajickova Katerina
, Kasalicky Petr
Denosumab discontinuation leads to loss of bone mineral density (BMD) achieved with treatment and in some patients to multiple vertebral fractures (VFx). Beyond bone, antiresorptive agents such as denosumab may affect breast cancer biology. We report a 69-year-old woman treated with the aromatase inhibitor anastrazole for breast cancer who suffered from five spontaneous vertebral fractures after denosumab cessation. Initially, she received four years of ibandronate followed by...